Lunai Bioworks and BrainStorm Therapeutics Team Up on AI-Driven Neurology Drug Discovery — Lunai Bioworks Inc.

Event summary

Lunai Bioworks' subsidiary BioSymetrics and BrainStorm Therapeutics announced a strategic collaboration on May 28, 2026, supported by a grant from the LouLou Foundation.
The partnership combines AI-driven target discovery, human brain organoid modeling, and in vivo validation to develop neurology assets for pharmaceutical partnering.
Initial focus areas include rare genetic epilepsies and Parkinson's disease, aligning with FDA guidance on innovative new approach methodologies (NAMs).
A flagship program targets a rare genetic epilepsy, with funding from the LouLou Foundation and collaboration with Dr. Calum MacRae at Brigham and Women's Hospital.

The big picture

The collaboration addresses the high failure rates in CNS drug development by integrating computational discovery with human-relevant biology and rapid functional validation. This approach aims to improve translational success and create multiple pathways for value creation, including strategic partnerships and non-dilutive funding. The partnership aligns with emerging FDA guidance encouraging the adoption of innovative methodologies that reduce dependence on traditional animal models.

What we're watching

Execution Risk: Whether the collaboration can efficiently progress programs from discovery through translational validation and external partnering.
Regulatory Alignment: How the adoption of innovative new approach methodologies (NAMs) will impact regulatory pathways and approval timelines.
Partnering Potential: The pace at which the collaboration can secure pharmaceutical partnerships, licensing agreements, or other value-generating opportunities.